TURKU, Finland and BOSTON, March 14, 2024 (GLOBE NEWSWIRE) — Fallon Pharmaceuticals, Inc. (AIM: FARN, First North: FARON) is developing a smart technology to reprogram bone marrow cells to activate antitumor activity. We are a clinical-stage biopharmaceutical company pursuing innovative approaches. The company, which develops the immune system in the blood and solid tumor microenvironment, today announced a virtual BEXMAB launch at 11.00 EET/09:00 GMT on Tuesday 19 March, following updated data cut-offs and scheduled analyses. We have announced that we will be holding an update event.
Webcast participants include Mika Kontro, MD, associate professor at the University of Helsinki and BEXMAB principal investigator; Faron’s Chief Scientific Officer, she is Maija Hollmen, Ph.D., Faron’s Chief Operating Officer, Juho Jalkanen, MD, and members of Faron’s senior management team.
During the event, the company will discuss the latest data from its ongoing BEXMAB trial in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), with a particular focus on durability of remission and objective response after treatment. We plan to discuss the following. Bexmarilimab In combination with standard treatment. This interactive event will also include an introduction to myeloid leukemia and insights into myeloid leukemia. of bexmarilimab Our latest understanding of unique mechanisms of action and early and long-term efficacy. Bexmarilimab process.Fallon also provides updates on of bexmarilimab Future development paths and business opportunities. Part of the discussion will be in Finnish and the summary will be in English.
You will have the opportunity to ask questions during the webcast. To register for the event, please visit https://faron.videosync.fi/bexmab-study-update/ or contact our IR team at investor.relations@faron.com for more information.
For more information, please contact us below.
Investor contact information
Life science advisor
daniel ferry
President
daniel@lifesciadvisors.com
+1 (617) 430-7576
media contact
ICR concilium
Mary-Jane Elliott, David Daley, Lindsay Neville
Phone: +44 (0)20 3709 5700
Email: faron@consilium-comms.com
Cairn Financial Advisors LLP, Nomad
Sandy Jamison, Joe Turner
Phone: +44 (0) 207 213 0880
Peel Hunt LLP, Broker
Christopher Golden, James Steele
Phone: +44 (0) 20 7418 8900
Sisu Partners Oy, NASDAQ First North Certified Advisor
Juha Kartonen
Phone: +358 (0)40 555 4727
Yucca yarbela
Phone: +358 (0)50 553 8990
About Bexumab
The BEXMAB study is an open-label, phase 1/2 clinical trial. Bexmarilimab In combination with standard of care (SoC) in advanced hematological malignancies such as acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). The primary objective is to determine the safety and tolerability of bexmarilimab in combination with SoC (azacytidine) therapy. Directly targeting Clever-1 could limit the replicative capacity of cancer cells, increase antigen presentation, and trigger an immune response, making current treatments more effective. Clever-1 is highly expressed in both AML and MDS and is associated with treatment resistance, limited T cell activation, and poor outcome.
About bexmarilimab
Bexmarilimab An investigational immunotherapy, wholly owned by Fallon, designed to target bone marrow cell function and activate the immune system to overcome resistance to existing treatments and optimize clinical outcomes. I am. Bexmarilimab It binds to Clever-1, an immunosuppressive receptor found on macrophages, causing tumor growth and metastasis (i.e., helping cancer evade the immune system). By targeting the Clever-1 receptor on macrophages, Bexmarilimab alters the tumor microenvironment, reprograms macrophages from an immunosuppressive (M2) state to an immunostimulatory (M1) state, upregulates interferon production, primes the immune system to attack the tumor, and increases standard therapy. sensitize cancer cells to
About Fallon Pharmaceuticals Co., Ltd.
Faron (AIM: FARN, First North: FARON) is a global clinical-stage biopharmaceutical company focused on tackling cancer with novel immunotherapies. Its mission is to bring the potential of immunotherapy to more people by discovering new ways to control and harness the power of the immune system.Our main assets are Bexmarilimaba novel anti-Clever-1 humanized antibody, has the potential to remove cancer immunosuppression through reprogramming myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential treatment for patients with blood cancers in combination with other standard treatments. For more information, please visit www.faron.com.
Forward-looking statements
Certain statements contained in this announcement are or may be deemed to be forward-looking statements. Forward-looking statements are identified by words such as “believes,” “may,” “should,” “expects,” “hopes,” “seeks,” “assumes,” “and” similar expressions. Identified by the use of phrases. “estimate,” “intend,” “may,” “plan,” “potentially,” “will,” or their negatives, variations, or comparisons (including references to assumptions); These forward-looking statements are not based on historical fact and are based on current statements made by our directors regarding our future growth, results of operations, performance, future capital and other expenditures, including their amounts, nature and sources. based on expectations and assumptions. , competitive advantage, business prospects and opportunities. Such forward-looking statements reflect the current beliefs and assumptions of the directors and are based on information currently available to them.
Many factors, many of which are beyond the Company’s control, could cause actual results to differ materially from the results and expectations described in the forward-looking statements. In addition, other factors that could cause actual results to differ materially include the Company’s ability to obtain licenses for the Program within the expected time period, general economic and business conditions, competitive and environmental conditions; , and other risks associated with vulnerability to regulatory changes. , actions by governmental authorities, availability of capital markets or other sources of financing, dependence on key personnel, uninsured and underinsured losses and other factors. Although the forward-looking statements contained in this announcement are based on what the directors believe to be reasonable, the Company cannot assure investors that actual results will correspond to such forward-looking statements. you can’t. Accordingly, readers are cautioned not to place undue reliance on forward-looking statements. Subject to our continuing obligations under applicable law or the requirements of the relevant AIM Regulations, in providing this information, we do not intend to publicly update or revise any forward-looking statements or to reflect any changes in events, conditions, etc. We have no obligation to notify you of changes in circumstances. Such statements are based on it.
